Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch Sagimet Bioscien...

Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch Sagimet Biosciences NASDAQ: SGMT said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China.